COMMUNIQUÉS West-GlobeNewswire

RAMSAY GENERALE DE SANTE has received competition clearance for the recommended public offer to the shareholders of Capio
16/10/2018
PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRIC A. THE OFFER IS NOT BEING MADE TO (AND [...]
RAMSAY GENERALE DE SANTE a reçu l'autorisation de l'Autorité de la concurrence dans le cadre de l'offre publique d'achat recommandée faite aux actionnaires de Capio
16/10/2018
COMMUNIQUE DE PRESSE LE PRESENT COMMUNIQUE DE PRESSE NE PEUT ETRE, DIRECTEMENT OU INDIRECTEMENT, DISTRIBUE OU PUBLIE EN AUSTRALIE, CANADA, HONG KONG, JAPON, NOUVELLE ZELANDE, OU AFRIQUE DU SUD. L'OFFRE N'EST PAS FAITE [...]
Notice of Extraordinary General Meeting in Immunicum AB (publ)
16/10/2018
Press Release 16 October 2018 Notice of Extraordinary General Meeting in Immunicum AB (publ) The shareholders of Immunicum AB (publ) (the "Company"), reg. no 556629-1786, hereby summon to Extraordinary General Meeting [...]
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
16/10/2018
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank Proceeds will be used to speed up development of pioneering lead product NBTXR3 and to support the European go- [...]
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement
16/10/2018
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement Le produit sera utilisé pour accélérer le développement du produit pionnier et leader [...]
Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy
16/10/2018
Press Release 16 October 2018 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, [...]
Rule 2.9 Announcement
16/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 16 October 2018 [...]
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
16/10/2018
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] In rheumatology, Cosentyx is [...]
Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
16/10/2018
Dupixent ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need [...]
Sanofi : Premiers résultats positifs de deux essais de phase III consacrés au Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne
16/10/2018
Premiers résultats positifs de deux essais de phase III consacrés au Dupixent ® (dupilumab) dans le traitement de la polypose nasosinusienne Dupixent a significativement réduit la taille des polypes, la congestion [...]
VALNEVA Announces Progress of Chikungunya Vaccine Candidate
16/10/2018
Valneva Announces Progress of Chikungunya Vaccine Candidate Saint Herblain (France), October 16, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech company focused on developing innovative [...]
VALNEVA annonce la progression du développement de son candidat vaccin contre le Chikungunya
16/10/2018
Valneva annonce la progression du développement de son candidat vaccin contre le Chikungunya Saint Herblain (France), 16 Octobre 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au [...]
INNATE PHARMA : data presentations on monalizumab at the ESMO annual meeting 2018
16/10/2018
INNATE PHARMA ANNOUNCES DATA PRESENTATIONS ON MONALIZUMAB AT The european society for medical oncology ANNUAL MEETING 2018 Management to host KOL call on updated data from the ongoing Phase II trial of monalizumab and [...]
INNATE PHARMA : présentation de données pour monalizumab lors du congrès annuel ESMO
16/10/2018
INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES POUR MONALIZUMAB LORS DU CONGRÈS ANNUEL DE LA SOCIÉTÉ EUROPÉENNE D'ONCOLOGIE MÉDICALE (ESMO) Une conférence téléphonique avec un leader d'opinion est organisée le lundi [...]
Probiodrug publishes SAPHIR data in peer reviewed journal
16/10/2018
Probiodrug publishes SAPHIR data in peer reviewed journal SAPHIR trial data published in Alzheimer's Research & Therapy HALLE (SAALE), Germany, 16 October 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical [...]
ICC Labs Provides Information About Circular
16/10/2018
VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. ( ICC or the Company ) (TSX-V: ICC) confirms that the management information circular dated October 3, 2018 (the Circular ), form of proxy and [...]
OpGen Provides Business and Preliminary Financial Update
15/10/2018
GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse [...]
Emblem Establishes Temporary “Patient Access Investment Fund” to Partially Cover Medical Cannabis Excise Tax
15/10/2018
Emblem will continue to advocate against the application of any tax on medical cannabis TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF ) ("Emblem" or the "Company") today announced that [...]
aTyr Pharma Announces Leadership Transition
15/10/2018
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]

Pages